Lenalidomide for relapsed or refractory multiple myeloma

<p>We report the activity of lenalidomide (revlimide – R), lenalidomide plus dexamethasone (Rd), lenalidomide plus bortezomib plus dexamethasone (RVd) in 34 patients with relapsed and refractory myeloma. For patients who received lenalidomide the overall response rate was 70.5 %. 38 % patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: S. S. Bessmeltsev1, E. V. Kariagina, L. V. Stelmashenko, G. N. Salogub, E. R. Machulaitene, K. M. Abdulkadyrov, N. A. Kotova, I. I. Kostroma, N. V. Medvedeva, L. I. Krylova, E. Yu. Ilushkina
Format: Artigo
Jezik:Russo
Izdano: ABV-press 2014-07-01
Serija:Onkogematologiâ
Teme:
multiple myeloma
lenalidomide
complete response
very good partial response
overall survival
Online dostop:http://oncohematology.abvpress.ru/index.php/ongm/article/view/64
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki